Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada...
The drug's failure is a bitter disappointment for patients and advocates...
Relyvrio's withdrawal leaves just three ALS medicines available to U.S. patients, only one of which has been shown to extend survival by several months.
Amylyx also said Thursday it will lay off 70% of its more than 350 employees as part of a major restructuring effort.
[
add
]
[
|
|
...
]